LivaNova (NASDAQ:LIVN) Reaches New 52-Week High – Should You Buy?

Shares of LivaNova PLC (NASDAQ:LIVN) hit a new 52-week high on Monday . The company traded as high as $84.30 and last traded at $83.81, with a volume of 24692 shares changing hands. The stock had previously closed at $83.62.

Analyst Ratings Changes

A number of equities analysts have recently commented on LIVN shares. Freedom Capital raised shares of LivaNova to a “hold” rating in a research report on Tuesday, June 30th. Robert W. Baird lowered their target price on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Weiss Ratings raised shares of LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research report on Thursday, May 7th. Barclays boosted their target price on shares of LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 7th. Finally, KeyCorp raised their price target on LivaNova from $83.00 to $92.00 and gave the company an “overweight” rating in a research report on Monday, June 22nd. Six investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $80.75.

LivaNova Stock Performance

The firm’s 50 day moving average price is $73.95 and its 200-day moving average price is $67.65. The firm has a market cap of $4.61 billion, a price-to-earnings ratio of 43.06 and a beta of 0.86. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.33 and a quick ratio of 1.11.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, May 6th. The company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.85 by $0.13. The firm had revenue of $362.26 million during the quarter, compared to analysts’ expectations of $346.05 million. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The business’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same period in the prior year, the company earned $0.88 EPS. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, analysts anticipate that LivaNova PLC will post 3.73 earnings per share for the current year.

Insider Buying and Selling at LivaNova

In related news, Director Francesco Bianchi sold 1,800 shares of LivaNova stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total transaction of $136,350.00. Following the sale, the director directly owned 7,228 shares of the company’s stock, valued at $547,521. This trade represents a 19.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.35% of the company’s stock.

Institutional Trading of LivaNova

A number of hedge funds have recently modified their holdings of the company. Hantz Financial Services Inc. increased its position in shares of LivaNova by 159.9% during the fourth quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock valued at $27,000 after purchasing an additional 267 shares during the period. State of Wyoming bought a new position in LivaNova in the second quarter worth $31,000. EverSource Wealth Advisors LLC boosted its stake in LivaNova by 998.4% during the second quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after buying an additional 639 shares in the last quarter. Quarry LP acquired a new stake in LivaNova during the third quarter worth $36,000. Finally, Covestor Ltd increased its holdings in LivaNova by 108.6% in the 4th quarter. Covestor Ltd now owns 753 shares of the company’s stock valued at $46,000 after buying an additional 392 shares during the period. Institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.